Does Xanomeline/Trospium Have Unique Benefits for Cognitive Impairment Associated With Schizophrenia?

What is it about?

The beneficial impact of the recently FDA-approved xanomeline and trospium chloride on cognitive impairment in schizophrenia is best understood in the context of similar data with a range of first- and second- generation antipsychotic agents. The absence of any head-head studies renders difficult any confident comparison of their therapeutic profiles in schizophrenia.

Featured Image